Quick Answer
Ovid Therapeutics Inc. reported Cash and Equivalents of $13.15 million for fiscal year 2025.
Ovid Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $13.15M | -50.0% |
| 2024 | $26.30M | -2.7% |
| 2023 | $27.04M | -39.7% |
| 2022 | $44.87M | -76.1% |
| 2021 | $187.80M | +160.7% |
| 2020 | $72.03M | +71.9% |
| 2019 | $41.90M | +14.8% |
| 2018 | $36.49M | -58.1% |
| 2017 | $87.13M | +67.7% |
| 2016 | $51.94M | -25.7% |
| 2015 | $69.94M | +1343.1% |
| 2014 | $4.85M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.61M | +37.3% | -27.5% |
| June 30, 2025 | $28.41M | -4.3% | +34.4% |
| March 31, 2025 | $21.14M | -31.3% | -19.6% |
| December 31, 2024 | $26.30M | -2.7% | +75.1% |
| September 30, 2024 | $15.02M | -73.9% | -49.4% |
| June 30, 2024 | $29.69M | -58.5% | -3.5% |
| March 31, 2024 | $30.77M | -51.2% | +13.8% |
| December 31, 2023 | $27.04M | -39.7% | -52.9% |
- Ovid Therapeutics Inc. showed a decrease of -50.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, Ovid Therapeutics Inc.’s cash and equivalents has grown by 171.4% (from $4.85 million to $13.15 million).
- The most recent figure is from Ovid Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: